Biocon gets US FDA approval for cancer biosimilar Pebrilzo; launch expected  in 2028 - Industry News | The Financial Express

Biocon has achieved a significant milestone in its oncology portfolio after receiving approval from the US Food and Drug Administration (FDA) for its 420 mg Pebrilzo injection, a medicine used in the treatment of certain breast cancer patients. The approval marks an important development for the Indian biopharmaceutical company as it continues to strengthen its presence in the global oncology market.

The regulatory clearance is expected to support Biocon’s efforts to expand access to cancer treatments in the United States, one of the world’s largest pharmaceutical markets. It also reflects the company’s growing focus on developing and commercialising affordable biologic medicines and cancer therapies.

What Is Pebrilzo (Pertuzumab)?

Pebrilzo, also known as pertuzumab-qcay, is a biosimilar version of Perjeta (pertuzumab), an established biologic medicine used in the treatment of HER2-positive breast cancer. It is a monoclonal antibody designed to target the HER2 receptor, a protein that can promote cancer cell growth when it is present at elevated levels.

By binding to the HER2 receptor, pertuzumab helps block signals involved in cancer cell proliferation. The medicine is used as part of a combination treatment approach, generally alongside trastuzumab and chemotherapy, depending on the patient’s cancer stage and treatment plan.

Pebrilzo is available in a 420 mg strength as a concentrate for intravenous infusion. The FDA approval provides another biosimilar treatment option in the HER2-positive breast cancer category.

FDA Approval Covers Early-Stage and Metastatic Breast Cancer

The US FDA approval allows Pebrilzo to be used in several treatment settings involving HER2-positive breast cancer in adults.

The medicine is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant setting, which means treatment before surgery. This approach may help manage the disease before the tumour is surgically removed.

It is also approved for adjuvant treatment following surgery in patients with early-stage HER2-positive breast cancer who are considered at high risk of recurrence.

In addition, Pebrilzo can be used with trastuzumab and docetaxel in adults with HER2-positive metastatic breast cancer who have not previously received anti-HER2 treatment or chemotherapy for metastatic disease.

These indications make the medicine relevant across different stages of treatment, although the final treatment choice depends on the patient’s clinical condition and the recommendations of the treating oncologist.

Biosimilar Medicines and Their Importance in Cancer Care

Biosimilar medicines are biologic products that are highly similar to an already approved reference medicine. They are developed after the original biologic product and undergo rigorous testing to establish that there are no clinically meaningful differences in safety, effectiveness and quality.

Unlike conventional generic medicines, biosimilars are made using complex biological processes. Their development requires detailed analytical testing, manufacturing controls and clinical or pharmacokinetic evidence, depending on regulatory requirements.

Biocon’s Pebrilzo approval is based on a comprehensive data package covering structural and functional characteristics, analytical similarity and comparative pharmacokinetic data. These assessments supported the FDA’s conclusion that the biosimilar meets the required standards for approval.

The introduction of biosimilars can help encourage competition in the biologic medicines market and potentially improve affordability and access to advanced treatments. However, actual cost savings for patients will depend on pricing, insurance coverage, market competition and commercial availability.

US Commercial Launch Expected in 2028

Although Pebrilzo has received FDA approval, its commercial launch in the United States is not expected immediately. Biocon has announced a global settlement and licence agreement with Genentech that secures the earliest licensed launch date for Pebrilzo in the US in the third quarter of calendar year 2028.

This arrangement provides clarity regarding the anticipated launch timeline and allows the company to plan its commercial strategy for the American market. The agreement is particularly important because the US is a major market for biologic cancer treatments, where biosimilars can play an increasingly important role in expanding treatment options.

The expected launch will be a key milestone for Biocon as it seeks to translate regulatory approval into commercial opportunities.

Biocon Strengthens Its Oncology Portfolio

Pebrilzo will become the fifth oncology biosimilar in Biocon’s US portfolio, further expanding the company’s position in cancer treatment. Its existing oncology products include:

  • Ogivri (trastuzumab-dkst): A biosimilar used in HER2-positive cancer treatment.

  • Jobevne (bevacizumab-nwgd): A biosimilar medicine used in several cancer treatment settings.

  • Fulphila (pegfilgrastim-jmdb): A medicine that helps reduce the risk of infection associated with chemotherapy-induced neutropenia.

  • Aukelso (denosumab-kyqq): A biologic medicine used in certain bone-related conditions, including cancer-related indications.

Biocon is also developing potential biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, reflecting its continued focus on expanding cancer treatment options.

Safety Considerations and Medical Monitoring

Like other pertuzumab-based medicines, Pebrilzo carries important safety considerations. The treatment may cause heart-related complications, including a reduction in left ventricular ejection fraction and heart failure. Doctors may therefore evaluate heart function before treatment and monitor it periodically during therapy.

The medicine also carries risks of infusion-related reactions, severe allergic reactions and embryo-fetal toxicity. Patients should be informed about these risks and monitored appropriately by healthcare professionals. The treatment is not suitable for individuals with known hypersensitivity to pertuzumab or its ingredients.

Common side effects associated with pertuzumab-based treatment regimens may include diarrhoea, nausea, fatigue, hair loss, neutropenia, rash and peripheral neuropathy, among others. The occurrence and severity of side effects can vary depending on the combination of medicines used.

Outlook for Biocon and the Biosimilar Market

The FDA approval of Pebrilzo represents an important achievement for Biocon as it continues to expand its global biosimilar business. The medicine strengthens the company’s oncology portfolio and adds another product targeting a major area of unmet medical need.

With growing demand for effective cancer therapies and increasing interest in biosimilars, Biocon is positioned to pursue further opportunities in the global healthcare market. The planned US launch in 2028 could become an important contributor to its future oncology business, subject to commercial execution and market conditions.

The approval also highlights the broader role of biosimilar medicines in improving competition and potentially widening access to biologic treatments. As Biocon continues to invest in research, development and manufacturing capabilities, its expanding oncology portfolio could support its long-term growth strategy while helping bring more treatment choices to patients worldwide.